Phosphorylation of neurofibromin by cAMP-dependent protein kinase is regulated via a cellular association of NG,NG-dimethylarginine dimethylaminohydrolase  by Tokuo, Hiroshi et al.
Phosphorylation of neuro¢bromin by cAMP-dependent protein kinase is
regulated via a cellular association of
NG,NG-dimethylarginine dimethylaminohydrolase
Hiroshi Tokuoa;b, Shunji Yunouea, Liping Fenga, Masumi Kimotoc, Hideaki Tsujic,
Tomomichi Onob, Hideyuki Sayaa, Norie Arakia;*
aDepartment of Tumor Genetics and Biology, Kumamoto University School of Medicine, 2-2-1 Honjo, Kumamoto 860-0811, Japan
bDepartment of Dermatology, Kumamoto University School of Medicine, 2-2-1 Honjo, Kumamoto 860-0811, Japan
cDepartment of Nutritional Science, Okayama Prefectural University, Kuboki, Soja, Okayama 719-1137, Japan
Received 21 February 2001; accepted 28 February 2001
First published online 20 March 2001
Edited by Julio Celis
Abstract The neurofibromatosis type 1 (NF1) tumor suppressor
(neurofibromin) is thought to play crucial roles in cellular Ras-
and cAMP-dependent kinase (PKA)-associated signals. In this
study, we identified a cellular neurofibromin-associating protein,
NG,NG-dimethylarginine dimethylaminohydrolase (DDAH) that
is known as a cellular NO/NOS regulator. The interaction of
DDAH was mainly directed to the C-terminal domain (CTD)
and to the cysteine/serine-rich domain (CSRD) of neurofibromin,
coinciding with the regions containing specific PKA phosphor-
ylation sites. DDAH increased PKA phosphorylation of native
neurofibromin in a dose-dependent manner, especially affecting
the phosphorylation of CSRD. These findings suggest that the
PKA accessibility of neurofibromin was regulated via DDAH
interaction, and this regulation may modulate the cellular
function of neurofibromin that is implicated in NF1-related
pathogenesis. ß 2001 Published by Elsevier Science B.V. on
behalf of the Federation of European Biochemical Societies.
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Neuro¢bromatosis type 1 (NF1) is a dominantly inherited
human disease a¡ecting one in 2500^3500 individuals [1,2].
The NF1 phenotype is highly variable with several organ sys-
tems being a¡ected, including bones, skin, iris, and the central
nervous system as manifested in learning disabilities and glio-
mas [2]. The hallmark of NF1 is the development of benign
tumors of the peripheral nervous system [1,2], and the in-
creased risk of developing malignancies [3,4]. The NF1 gene
lies on chromosome 17q11.2 [5,6], and the great majority of
patient mutations prevent the expression of the intact NF1
product, neuro¢bromin [7]. Neuro¢bromin contains a central
domain homologous to a family of proteins known as Ras-
GTPase-activating proteins (Ras-GAPs), which function as
negative regulators for Ras proteins [8]. Ras-GAPs attenuate
signaling from Ras, thus blocking the transmission of signals
leading to increased growth or di¡erentiation. However, the
precise function of cellular neuro¢bromin, on either Ras-de-
pendent signals or on NF1-related pathogenesis, has not been
clearly elucidated.
Recently some interesting studies have reported that Dro-
sophila NF1 acts as a possible activator of the cAMP pathway
that involves the rutabaga (rut)-encoded adenylyl cyclase
[9,10]. The mechanism of the NF1-dependent activation of
the cAMP pathway was suggested being essential for mediat-
ing Drosophila learning and memory. From this evidence,
neuro¢bromin has been thought to play a crucial role in cel-
lular functions linked to cAMP-dependent protein kinase
(PKA)-associated signals as well as to Ras-GAP signals in
major cellular pathways.
Izawa et al. reported that neuro¢bromin is constitutively
phosphorylated, and that the speci¢c phosphorylation lie on
the cysteine/serine-rich domain (CSRD) and the C-terminal
domain (CTD) of neuro¢bromin [11]. in vitro and in gel ki-
nase assays suggest that PKA is a candidate for the neuro-
¢bromin kinase [11]. Although the biological signi¢cance of
the PKA phosphorylation of neuro¢bromin has not been
clear, these ¢ndings prompt us to speculate that cellular neu-
ro¢bromin is regulated post-translationally by several cellular
factors.
Most of the NF1 mutations are nonsense, frame shift, or
truncating mutations leading to premature termination co-
dons [7,12], and a relative high frequency of the mutation
has been reported down stream of the GAP-related domain
(GRD) to the C-terminal region [12]. This suggests that the C-
terminal region of neuro¢bromin is important in regulating
the tumor suppressive function of neuro¢bromin. In this con-
text, identi¢cation and analysis of cellular proteins that are
bound to C-terminal neuro¢bromin is thought to be crucial to
elucidate the biological signi¢cance of neuro¢bromin.
In this study, we attempted to purify a cellular neuro¢bro-
min-interacting protein from a bovine brain cytosolic fraction
using a⁄nity column immobilized CTD of neuro¢bromin,
and identi¢ed it as NG,NG-dimethylarginine dimethylamino-
hydrolase (DDAH). The binding region of DDAH was found
on the CSRD as well as CTD that was happened to coincide
with the region containing the speci¢c PKA phosphorylation
sites of neuro¢bromin. Thus, we analyzed the e¡ects of
DDAH in PKA phosphorylation of neuro¢bromin, and
showed that DDAH clearly increased the PKA phosphoryla-
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tion accessibility of neuro¢bromin. Consequently, we postu-
lated that the cellular binding proteins of neuro¢bromin, such
as DDAH, might modulate both the PKA-related signals and
the Ras-associated signals of neuro¢bromin.
2. Materials and methods
2.1. Preparation of GST fusion neuro¢bromin fragments
PGEX-2TH plasmids harboring NF1-domain cDNAs, which gen-
erate GST^GRD fusion protein (residues 1168^1545), CSRD: 543^
909, leucine repeat domain (LRD: 1530^1950), and CTD: 2262^2818
respectively, were constructed as described previously [11]. For
pGEX-CTD1000 (2262^2619), a fragment of the 3P-end region in
the CTD insert was cut o¡ from the pGEX-CTD with the double
digestion of the EcoRI and HindIII sites, blunt-ended by T4 DNA
polymerase, self-ligated and subcloned. For pGEX-CTD600 (2620^
2818), 600 bases of fragment containing the 3P-end of the CTD was
cut out by the double digestion of EcoRI and AatII sites from pGEX-
CTD, inserted into the EcoRI and AatII sites of pGEX-2TH and
subcloned. We con¢rmed the entire sequences of the insert of all
newly constructed plasmids were identical to the reported sequences
by DNA sequencing analysis. Expression and puri¢cation of each
GST fusion protein were performed according to the original protocol
as described previously [13,14].
2.2. Expression and puri¢cation of DDAH
A native DDAH was puri¢ed from rat kidney as described previ-
ously [15]. GST^DDAH was prepared from pGEX-DDAH according
to the original protocol as previously described [13]. A mammal ex-
pression vector pbj-Myc-DDAH was constructed with an insertion of
BamH1 fragment from pGEX-DDAH to a pbj-Myc BamH1 cloning
site and cloned. To express myc-tagged DDAH, the pbj-Myc-DDAH
was transfected into COS7 cells by the liposome-mediated gene trans-
fection method.
2.3. Antibodies
Antibodies against GST^CSRD and GST^GRD type 1 fusion pro-
teins were raised and puri¢ed from male Fisher 344 rats sera. Anti-
body against C-terminal (D) neuro¢bromin was purchased from San-
ta Cruz Biotechnology. Mouse monoclonal antibody against native
rat DDAH was prepared as described previously [16]. The anti-Myc
monoclonal antibody was prepared from 9E10 cells.
2.4. Preparation of cytosolic fraction from bovine and rat brain
Cytosolic fraction of bovine brain was prepared as previously de-
scribed [17]. In brief, bovine brain gray matter was cut into small
pieces and suspended in homogenizing bu¡er A (25 mM Tris^HCl,
pH 7.5, 1 mM dithiothreitol, 5 mM EGTA, 10 mM MgCl2, 10%
sucrose), homogenized with a Potter^Elvehjem Te£on glass homoge-
nizer, and centrifuged at 12 000 rpm for 30 min. Solid ammonium
sulfate was added to the supernatant to 40% saturation, and the
mixture was centrifuged. To the supernatant of the centrifugates, solid
ammonium sulfate was subsequently added to 80% saturated, and
then centrifuged. The precipitate was dialyzed against bu¡er A, and
used as the cytosolic 40^80% fraction. For the rat brain cytosolic
fraction, rat brain was homogenized with bu¡er B (20 mM Tris^
HCl, pH 7.5, 1 mM EDTA, 5 mM MgCl2, 150 mM NaCl, 0.1%
NP-40, 1 mM 4-(2-aminoethyl)-benzenesulfonyl £uoride hydrochlo-
ride (p-ABSF), 20 Wg/ml aprotinin, 1.5 WM pepstatin A, 10 Wg/ml
leupeptin, and 500 WM sodium orthovanadate) in a dance type ho-
mogenizer. The homogenized sample was centrifuged at 14 000 rpm
for 20 min, and the supernatant was used for the experiments. All
experiments described were performed at 4‡C or on ice.
2.5. Detection of binding proteins from brain cytosolic fraction by
GST^CTD a⁄nity chromatography
The GST^CTD fusion protein immobilized on GSH-agarose was
packed into a column, and equilibrated with bu¡er C (30 mM Tris^
HCl, pH 7.5, 1 mM EDTA, 5 mM MgCl2, 1 mM dithiothreitol).
Bovine brain cytosolic fraction, pre-cleared by passing it through a
GSH column, was then loaded onto the GST^CTD column. After
washing the column with bu¡er C, the protein bound to the column
was eluted by the addition of bu¡er D (bu¡er A containing 0.5 M
NaCl), and subjected to SDS^PAGE, followed by silver staining.
2.6. Puri¢cation of p35 and determination of peptide
To purify a 35-kDa protein (p35), the binding proteins eluted from
the column were dialyzed against distilled water. After concentration
of the solution by evaporation, the sample was subjected to SDS^
PAGE, transferred onto a PVDF membrane (ABI), and stained
with Ponceau S. A stained band of p35 was cut out from membrane,
reduced S-pyridylethylated, and digested by Achromobacter protease I
(Wako) for 48 h. After sonication and centrifugation, the supernatant
was loaded onto a reverse-phase HPLC (Hitachi L655-15) using a
W-Bondasphere C8 column (Waters). The HPLC fractions were sub-
jected to amino acid sequencing using the 492 Procise protein se-
quencing system (PE Applied Biosystems). Amino acid sequences ob-
tained were subjected to SwissProt, EST-DATA base and BLAST
sequence homology search analyses.
2.7. Interaction of DDAH with neuro¢bromin in vitro
Various GST fusion fragments of neuro¢bromin or GST immobi-
lized to GSH-agarose beads were incubated with DDAH puri¢ed
from GST^DDAH after PreSission protease digestion or COS7 cell
lysates overexpressing myc-DDAH, for 2 h at 4‡C. After washing
three times with bu¡er B, the protein bound to the beads were eluted,
subjected to SDS^PAGE, electroblotted onto the membrane, and then
probed with the anti-DDAH or anti-myc antibodies. After reaction
with the HRP-conjugated secondary antibodies, the reacted protein
band on the membrane was visualized by an ECL detection system
(Amersham).
2.8. Interaction of DDAH with cellular endogenous neuro¢bromin
Subcon£uently grown SH-SY5Y cells were lysed in bu¡er B, and
centrifuged at 14 000 rpm for 30 min at 4‡C. The supernatant was
incubated with GST or GST^DDAH immobilized GSH beads. COS7
cells over expressing myc-DDAH were lysed in bu¡er B after 48 h of
transfection. The lysates were centrifuged at 14 000 rpm for 30 min at
4‡C, and the supernatant immunoprecipitated with an anti-myc
monoclonal antibody, or mouse IgG as a negative control. The pro-
teins bound on each beads were separated through SDS^PAGE, elec-
troblotted onto the membrane and detected by the immunoblotting
being probed with the anti-neuro¢bromin antibody (D). After reac-
tion with HRP-conjugated secondary antibodies, the reacted protein
band on the membrane was visualized by an ECL detection system.
2.9. Phosphorylation assay of neuro¢bromin by PKA
Con£uently grown HeLa cells were lysed in bu¡er B containing 10
mM NaF. After centrifugation of the cell lysates, the supernatant was
incubated with rat anti-GRD polyclonal antibody conjugated on
CNBr-activated Sepharose 4B beads (Amersham Pharmacia) at 4‡C
for 2 h. After the incubation, the bound neuro¢bromin on the beads
was washed three times with bu¡er B, once with the starting bu¡er (20
mM Na-phosphate bu¡er, pH 7.0), and eluted with the elution bu¡er
(100 mM glycine HCl pH 2.7), followed by the neutralization with 1 M
Tris^HCl. In vitro kinase reactions for the eluted endogenous neuro-
¢bromin were carried out in a reaction bu¡er of a ¢nal volume of 50
Wl, containing 25 mM sodium acetate, 2 mM MgCl2, 10 WCi of
[Q-32P]ATP (3000 Ci/mmol), and 5 Wl neuro¢bromin (1 Wg) with 2 units
of PKA catalytic subunit at 37‡C for 10 min without or with PKA
inhibitor. The reaction mixtures were then subjected to SDS^PAGE
(6%), and [32P]phosphate-labeled neuro¢bromin on the gel was de-
tected by autoradiography using a BAS 2000 (Fuji Photo Film)
with Image Reader Ver. 1.3 and Mac Bas V2.5 software.
3. Results
3.1. Identi¢cation of neuro¢bromin-associating proteins
To purify neuro¢bromin-binding proteins, bovine brain cy-
tosolic fraction was loaded on GSH columns to which GST^
CTD or GST were immobilized, and the proteins bound to
the columns were eluted with a high salt bu¡er. Eight proteins
with molecular masses of 175, 97, 45, 35, 30, 27, 26 and 19
kDa were obtained from the GST^CTD column, but none of
them were obtained from the GST column (Fig. 1A).
To identify the 35-kDa protein (p35), p35 was puri¢ed and
digested by lysyl end-peptidase. After peptide separation of
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the digested p35 with reverse-phase HPLC (C8), they were
subjected to amino acid sequencing. Six peptide sequences
derived from p35 were determined. These were EALEK,
LQLNIVEMK, XTNQXGAEIL, DYAVSTVPV, SFCSM-
AGPN, IMQQMS, and GHVLLHRTPE (Fig. 1B). All these
identi¢ed sequences were found in the sequences of rat
DDAH [18] (Fig. 1B). The calculated molecular mass of rat
DDAH was 31 121 Da, which was close to the apparent mo-
lecular mass of p35 estimated by SDS^PAGE. We further
con¢rmed that p35 is DDAH by immunoblot analysis using
an antibody raised against rat DDAH [16]. Puri¢ed rat
DDAH was used for a positive authentic control. An immu-
noreactive band was detected at 35 kDa in the eluates from
the GST^CTD column subjected to the bovine brain extracts
but not in the eluates from the GST column (Fig. 2A). The
human DDAH (human DDAH has 98% homology to rat
DDAH) has been recently cloned by Kimoto et al. [19].
DDAH is known as a regulator for MMA (NG-monometh-
yl-L-arginine) and DMA (NG,NG-dimethyl-L-arginine), sub-
strate analogues of NO synthase (NOS), and is thought to
be a NOS/NO endogenous regulator, controlling the metabo-
lism of MMA and DMA in a variety of cells and tissues [19].
The other neuro¢bromin-interacting proteins identi¢ed in this
experiment will be described elsewhere.
3.2. Interaction of DDAH and neuro¢bromin in vitro and
in vivo
To evaluate interaction of between DDAH and neuro¢bro-
min, bacterially expressed and puri¢ed recombinant DDAH
was incubated with GSH beads, which immobilized either
GST^CTD or GST. Recombinant DDAH were retained
only on the GST^CTD beads but not on the GST beads
(Fig. 2B). These results suggest the direct interaction of
DDAH and neuro¢bromin in vitro. To address whether
DDAH could also interact with endogenous neuro¢bromin,
human neuroblastoma SH-SY5Y cell lysates were analyzed by
the pull-down assay using GSH beads, which immobilized
either GST^DDAH or GST. The neuro¢bromin (240 kDa)
was precipitated only with the GST^DDAH beads, but not
with the GST beads (Fig. 2C), suggestive of the apparent
interaction of endogenous neuro¢bromin and DDAH. To en-
sure an interaction of neuro¢bromin and DDAH in vivo, cell
extracts prepared from COS7 cells that overexpressed myc
epitope-tagged DDAH (myc-DDAH) were precipitated with
the antibody against myc-epitope (9E10). Immunoblot analy-
sis of the immunoprecipitates using the anti-neuro¢bromin
antibody revealed that endogenous neuro¢bromin was co-pre-
cipitated with myc-DDAH (Fig. 2D, lane 3). These results
indicate that neuro¢bromin and DDAH form a complex in
vivo as well as in vitro.
3.3. Speci¢c binding sites of DDAH on neuro¢bromin
To determine which region of neuro¢bromin interacts with
DDAH, various fragments of neuro¢bromin fused to GST
(Fig. 3A) immobilized on GSH-beads were prepared, and re-
acted with myc-DDAH overexpressed in COS7 cells. As
shown in Fig. 3B and C, myc-DDAH strongly interacted
with GST^CTD 600, slightly with GST^CSRD and GST^
Fig. 1. Detection of Neuro¢bromin-interacting proteins (A), and ho-
mology analysis of amino acid sequences of p35 vs. rat DDAH (B).
A: Brain proteins bound to the a⁄nity columns, either immobilized
GST^CTD or GST, were subjected to SDS^PAGE followed by sil-
ver staining. The molecular mass (kDa) is indicated on the left. The
arrows indicate the positions of the speci¢c binding proteins. B: In-
ternal amino acid sequences of p35 identi¢ed are underlined in the
complete amino acid sequence of rat DDAH [18].
Fig. 2. Interaction of neuro¢bromin and DDAH. A: Immunoreac-
tivity of anti-DDAH antibody against p35 in the brain proteins
eluted from GST^CTD (lane 2) or GST column (lane 1). B: The re-
combinant DDAH puri¢ed from GST^DDAH after PreScission
protease digestion was incubated with the GST^CTD (lane 2) or
GST (lane 1) beads, and the interacted DDAH on each beads was
detected with anti-DDAH antibody. The arrowheads indicate the
position of DDAH. C: The lysates of SH-SY5Y cells were incu-
bated with GST (lane 1) or GST^DDAH (lane 2) beads, and the in-
teracted DDAH on each beads was detected with an anti-neuro¢-
bromin antibody. D: The cell lysates prepared from COS7 cells
expressing myc-DDAH were immunoprecipitated with mouse IgG
(lane 1), anti-NF1-GRD antibody (lane 2) or anti-myc antibody
(lane 3). The immunoprecipitates were analyzed by immunoblotting
probed with an anti-neuro¢bromin (D) antibody. The arrows indi-
cate the position of endogenous neuro¢bromin.
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CTD 1000, but not with other domains or GST. These results
suggest that DDAH could interact not only with CTD but
also with CSRD. The DDAH-binding activity to both CSRD
and CTD in their mixture was accountable without any addi-
tional increase or decrease (Fig. 3C), suggesting that CTD and
CSRD interact independently with DDAH in this experimen-
tal condition.
3.4. E¡ect of DDAH on PKA phosphorylation of
neuro¢bromin
Interestingly, the DDAH-binding regions of neuro¢bromin
(CSRD, CTD) were found to coincidently contain the sites for
PKA phosphorylation [11]. This prompted us to speculate
that DDAH acts as a regulator for PKA phosphorylation of
neuro¢bromin. To evaluate the signi¢cance of DDAH inter-
action with neuro¢bromin, we next analyzed the e¡ect of
DDAH on PKA phosphorylation of cellular neuro¢bromin
puri¢ed from HeLa cells by an in vitro kinase reaction using
PKA catalytic fragments. The results showed that neuro¢bro-
min was signi¢cantly phosphorylated by PKA, and the phos-
phorylation was increased in the presence of GST^DDAH in
a dose-dependent manner (Fig. 4A). This PKA phosphoryla-
tion was completely inhibited by the presence of PKA inhib-
itor (data not shown). However, neither GST (Fig. 4A) nor
BSA (data not shown) could increase neuro¢bromin phos-
phorylation. The maximum e¡ect of GST^DDAH on neuro-
¢bromin phosphorylation was up to 12.5 times higher than
that of GST or BSA (Fig. 4B). No e¡ects of GST^DDAH on
the increase of PKA phosphorylation on myelin basic protein
(MBP), an authentic substrate used in typical PKA kinase
assays, were observed (Fig. 5). These results strongly suggest
that DDAH has no direct e¡ects on PKA kinase activity, but
up-regulates the PKA phosphorylation accessibility of neuro-
¢bromin.
Finally, to further evaluate the PKA phosphorylation of
neuro¢bromin, we analyzed the phosphorylation region that
would be a¡ected by the DDAH interaction. The PKA phos-
phorylation was observed only on CSRD and CTD, and not
on other domains such as GRD (Fig. 5A); consistent with the
results reported by Izawa et al. [11]. However, the dose-de-
pendent e¡ect of DDAH on the increase of PKA phosphor-
ylation was signi¢cantly observed on CSRD but little on CTD
(Fig. 5). These results suggest that the interaction of DDAH
with neuro¢bromin a¡ects the accessibility of PKA phosphor-
ylation, especially on CSRD.
Fig. 3. Interaction of neuro¢bromin fragments with DDAH. A: The
GST^neuro¢bromin fragments used are schematically represented.
B, C: Myc-DDAH over expressed in COS7 cells were reacted with
GST or GST fusion neuro¢bromin fragments (GST^CSRD, GRD,
LRD, CTD1000, CTD600) immobilized onto GSH-agarose beads.
Myc-DDAH bound on the beads was detected by immunoblotting
probed with an anti-myc monoclonal antibody. The arrows indicate
the position of myc-DDAH.
Fig. 4. E¡ects of DDAH on PKA phosphorylation of cellular neu-
ro¢bromin. A: Cellular endogenous neuro¢bromin prepared from
HeLa cell lysates was incubated with various concentrations of
GST^DDAH or GST, and reacted with PKA catalytic subunits in
the presence of [Q-32P]ATP. The phosphorylated proteins were sepa-
rated through 6% SDS^PAGE, and analyzed by autoradiography.
The arrows indicate the position of neuro¢bromin. B: Relative in-
tensities of phosphorylation rates of neuro¢bromin in each sample
tested were calculated by Mac Bass, and plotted on the graph. Data
represent mean of duplicate experiments, and the ¢gure is a repre-
sentative of three independent experiments.
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4. Discussion
In this study, we demonstrate a new neuro¢bromin-binding
protein, DDAH, that regulates the speci¢c PKA phosphory-
lation of neuro¢bromin. At the ¢rst step of this study, we
identi¢ed DDAH as a cellular associating protein of the
C-terminal region of neuro¢bromin, since we used the CTD
a⁄nity column to detect and purify it. Because most of the
NF1 mutations cause the C-terminal truncated type of neuro-
¢bromin [7,12], it is suggestive that the C-terminal region of
neuro¢bromin is crucial in the neuro¢bromin function, and
the CTD-binding proteins such as DDAH may work as func-
tional regulators of neuro¢bromin. Indeed, in this study,
DDAH was demonstrated as a regulatory factor to increase
the PKA accessibility of neuro¢bromin.
Surprisingly, several binding assays indicate that DDAH
could associate not only with CTD but also with CSRD
(Fig. 3). Fahsold et al. recently reported that unlike truncating
mutations, missense or single amino acid deletion mutations
were identi¢ed clustered in CSRD and GRD, and so, they
assumed that CSRD is a second functional domain of the
neuro¢bromin molecule [7]. The CSRD comprises amino
acid residues 543^909, in which the ATP-binding domain
and three potential PKA recognition sites (residues 586T,
818S, 876S) are contained [20]. The speci¢c PKA phosphory-
lation of CSRD was con¢rmed in this study as well as in the
previous report [11]. Under the presence of DDAH, CSRD
was the most sensitive region for the PKA phosphorylation in
the neuro¢bromin fragments (Fig. 5), although the binding
activity of CSRD to DDAH was much weaker than that of
CTD (Fig. 3). The increase of PKA phosphorylation on
CSRD was independent of the PKA catalytic activation by
DDAH, because DDAH could not increase PKA phosphor-
ylation of other PKA substrates such as MBP (Fig. 5). These
¢ndings led us to conclude that neuro¢bromin-binding protein
DDAH increases the PKA phosphorylation accessibility of
the CSRD. Since a small region (residues 815^834) of the
CSRD sequence similar to MAP-2 and tau were reported to
associate with microtubules [21], it is speculated that the reg-
ulation of PKA phosphorylation by DDAH as well as DDAH
interaction on this region might modulate the neuro¢bromin
association to microtubules, or other cellular factors. The in-
crease of the PKA phosphorylation of the puri¢ed cellular
neuro¢bromin by DDAH was more signi¢cantly observed
than that of GST^CSRD (Fig. 4). Thus, it is speculated that
DDAH binding to CTD may cause alteration of the tertiary
structure of the endogenous neuro¢bromin to increase the
PKA accessibility on CSRD.
DDAH is an enzyme that is known to metabolize endoge-
nous NOS inhibitors such as MMA and DMA to citrulline.
The expression of DDAH protein was widely distributed in
rat, particularly, in kidney, pancreas, liver, brain and aorta at
high concentrations [16]. Methylarginines including MMA
and DMA are now known to exist endogenously in immune
cells and in the brain [16,22], and to inhibit NOS [23,24],
suggesting that DDAH contributes to the control of NOS
and NO in vivo. The subcellular localization of DDAH has
not been revealed precisely, except that it is localized in the
cytoplasm of kidney and brain cells that was analyzed immu-
nocytochemically [25] and biochemically [26]. This was also
evident in this study where DDAH was detected in the cyto-
plasmic fraction of rat and bovine brain (Figs. 1 and 2). On
the other hand, evidence for the neuro¢bromin localization in
cytoplasm has been reported [27^31] with some controversial
pieces of results on its precise localization. We have detected
the endogenous neuro¢bromin biochemically in the cytoplas-
mic fraction from rat and bovine brains, mouse ¢broblasts,
HeLa cells, and human neuroblastoma cells. These results
suggest that neuro¢bromin and DDAH may co-localize at
least in the cellular cytoplasmic region.
Drosophila NF1 acts as a possible activator of the rut-en-
coded adenylyl cyclase, and the mechanism of the NF1-depen-
dent activation of cAMP pathway was suggested being essen-
tial for mediating Drosophila learning and memory [10]. Our
results, however, suggest that activation of cAMP pathway
regulates the neuro¢bromin function, since neuro¢bromin is
speci¢cally phosphorylated by PKA. Thus, it is speculated
that neuro¢bromin function may involve at least two
cAMP-related pathways, namely, the neuro¢bromin-depen-
dent activation of cAMP pathway and the cAMP-dependent
activation of the neuro¢bromin signal pathway. Further study
would be able to make clear the precise mechanism of the
PKA relation to the neuro¢bromin functions. Particularly, it
would be important to study the e¡ect of PKA phosphoryla-
tion and its regulation of neuro¢bromin on cellular Ras-
MAPK signals.
Fig. 5. E¡ects of DDAH on the PKA phosphorylation of CSRD,
GRD, CTD600, and MBP. A: In vitro kinase reactions of PKA
against GST fusion fragments CSRD, GRD, CTD600, and MBP
were performed with various concentrations of GST^DDAH (lane
1, 0; lane 2, 10 ng; lane 3, 0.1 Wg; lane 4, 1.0 Wg/system). After the
reaction was stopped, the phosphorylated proteins were analyzed by
autoradiography. B: Relative intensity ratios (I/I0) of PKA phos-
phorylation on GST^CSRD (b), CTD (F), and MBP (R) (I/I0 ;
PKA phosphorylation intensity of sample reacted with DDAH (I)/
PKA phosphorylation intensity of samples reacted without DDAH
(I0)). Data represent mean of duplicate experiments, and the ¢gure
is a representative of three independent experiments.
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Our preliminary study using embryonic ¢broblast cells of
Nf1 gene knock-out mouse showed that DDAH catalytic ac-
tivity to convert MMA to citrulline in those cells was signi¢-
cantly higher than that in Nf1 gene wild type mouse cells
(unpublished data). We speculate that the functional regula-
tion of DDAH as a NO/NOS regulator may also have some
links to neuro¢bromin function and neuro¢bromin-related
signals, although those mechanisms have to be further ana-
lyzed more precisely.
While the functional signi¢cance of the PKA phosphoryla-
tion of neuro¢bromin is still unclear, the e¡ect of the regula-
tion of PKA phosphorylation on cellular neuro¢bromin by
DDAH may be an important cellular event controlling phys-
iological states. The results of this study provide new insight
into the mechanisms of the functional regulation of cellular
neuro¢bromin that is strongly linked to NF1-related tumor
generation and various other pathogeneses.
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